Mechanisms for the formation of glycoxidation products in end-stage renal disease

Kidney International

Volumn 57, Issue 6, 2000, Pages 2571-2585

  Weiss, Miriam F ^a   Erhard, Penny ^a   Kader Attia, Fatma A ^a   Wu, Yu Ching ^a   Deoreo, Peter B ^a   Araki, Atsushi ^a   Glomb, Marcus A ^a   Monnier, Vincent M ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Advanced glycation end products; High flux dialysis; N( )(carboxymethyl)lysine; Pentosidine; Uremia

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CHELATING AGENT; LYSINE DERIVATIVE; PENTOSIDINE;

ARTICLE; CATALYSIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MOLECULAR WEIGHT; OXIDATIVE STRESS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REACTION ANALYSIS; UREMIA;

EID: 0034120352     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2000.00117.x     Document Type: Article

References (51)

1. 1. MIYATA T, HORI O, ZHANG J, YAN S, FERRAN L, IIDA Y, SCHMIDT A: The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-β2 microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway: Implications for the pathogenesis of dialysis-related amyloid. J Clin Invest 98:1088-1094, 1996
2. 2. MlYATA T, NOTOYA K, YOSHIDA K, HORlE K, MAEDA K, KUROKAWA K, TAKETOMI S: Advanced glycation end products enhance osteoclast-induced hone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles. J Am Soc Nephrol 8:260-270, 1997
3. 3. MIYATA T, VAN YPERSELE DE STRIHOU C, KUROKAWA K, BAYNES J: Alterations in nonenzymatic biochemistry in uremia: Origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int 55:389-399, 1999
4. 4. RITZ E, DEPPISCH R, NAWROTH P: Toxicity of uraemia: Does it come of AGE? Nephrol Dial Transplant 9:1-2, 1994
5. 5. VLASSARA H: Serum advanced glycosylation end products: A new class of uremic toxins? Blood Purif 12:54-59, 1994
6. 6. MONNIER VM, SELL DR, MIYATA S, NAGARAJ RH, ODETTI P, LAPOLLA A: Advanced Maillard reaction products as markers for tissue damage in diabetes and uraemia: Relevance to diabetic nephropalhy. Acta Diabetol 29:130-135, 1992
7. 7. MAKITA Z, BUCALA R, RAYFIELD EJ, FRIEDMAN EA, KAUFMAN AM, KORBET SM, BARTH RH, WINSTON JA, FUH H, MANOGUE KR, CERAMI A, VLASSARA H: Reactive glycosylation endproducts in diabetic uremia and treatment of renal failure. Lancet 343:1519-1522, 1994
8. 8. FRIEDLANDER M, WU Y, SCHULAK J, MONNIER V, HRICIK D: Influence of dialysis modality on plasma and tissue concentrations of pentosidine in patients with end-stage renal disease. Am J Kidney Dis 25:445-451, 1995
9. 9. FRIEDLANDER M, WU Y, ELGAWISH A, MONNIER V: Early and advanced glycosylation end products: Kinetics of formation and clearance in peritoneal dialysis. J Clin Invest 97:728-735, 1996
10. 10. MIYATA T, UEDA Y, SHINZATO T, IIDA Y, TANAKA S, KURAKAWA K, VAN YPERSELE DE STRIHOU C, MAEDA K: Accumulation of albuminlinked and free-form pentosidine in the circulation of uremic patients with end stage renal failure: Renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol 7:1198-1206, 1996
11. 11. MIYATA T, FU M-X, KUROKAWA K, VAN YPERSELE DE STRIHOU C, THORPE S, BAYNES J: Autoxidation products of both carbohydrates and lipids arc increased in uremic plasma: Is there oxidative stress in uremia? Kidney Int 54:1290-1295, 1998
12. 12. GUGLIUCCI A, BENDAYAN M: Renal fate of circulating advanced glycated end products (AGE): Evidence for reabsorption and catabolismof AGE-peptides by renal proximal tubular cells. Diabetologia 39:149-160, 1996
13. 13. MIYATA T, UEDA Y, HORIF K, NANGAKU M, TANAKA S, SIRIHOU CVD, KUROKAWA K: Renal catabolism of advanced glycation end products: The fate of pentosidine. Kidney Int 53:416-422, 1998
14. 14. SELL DR, MONNIER VM: End-stage renal disease and diabetes catalyze the formation of a pentose-derived crosslink from aging human collagen. J Clin Invest 85:380-384, 1990
15. 15. AHMED M.THORPE S, BAYNES J: Identification of Nε-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 261:4889-4894, 1986
16. 16. NIWA T, KATSUZAKI T, MIYAZAKI S, MIYAZAKI T, ISHIZAKI Y, HAYASE F, TATEMICHI N, TAKEI Y: Immunohistochemical detection of imidazalone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. J Clin Invest 99:1272-1280, 1999
17. 17. SELL D, MONNIER V: Structure elucidation of a senescence crosslink from human extracellular matrix. J Biol Chem 264:21597-21602, 1989
18. 18. DYER DG, BLACKLEDGE JA. THORPE SR, BAYNES JW: Formation of pentosidine during nonenzymatic browning of proteins by glucose: Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 266:11654-11660, 1991
19. 19. GRANDHEE S, MONNIER V: Mechanism of formation of the Maillard protein cross-link pentosidine. J Biol Chem 266:11649-11653, 1991
20. 20. FU M-X, WELLS-KNECHT KJ, BLACKLEDGE JA, LYONS TJ, THORPE SR, BAYNES JW: Glycation, glycoxidation, and cross-linking of collagen by glucose. Diabetes 43:676-683, 1994
21. ε-(carboxymethyl) lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 271:9982-9986, 1996
22. 22. GLOMB M. MONNIER V: Mechanism of protein modification by glyoxal and glycoaldehyde, reactive intermediates of the Maillard reaction. J Biol Chem 270:10017-10026, 1995
23. 23. ANDERSON M, HAZEN S, HSU F, HEINECKE J: Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycoaldehyde, 2-hydroxypropanal and acrolein: A mechanism for the generation of highly reactive α-hydroxy and α,β-unsaturated aldehydes by phagocytes at sites of inflammation. J Clin Invest 99:397-403, 1997
24. 24. MIYATA T, UEDA Y, YOSHIDA A, SUGIYAMA S, IIDA Y, JADOUL M, MAEDA K, KURAKAWA K, VAN YPERSELE DE SIRIHOU C: Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy. Kidney Int 51:880-887, 1997
25. 25. KESHAVIAH P: Adequacy of CAPD: Quantitative approach. Kidney Int 42(Suppl):S160-S164, 1992
26. 26. LENTNER C: Geigy Scientific Tables (8th ed). Basle, CIBA-GEIGY, Ltd., 1981
27. 27. INGALLS S, XU Y, HOPPEL C: Determination of plasma non-esterified fatty acids and triglyceride fatty acids by gas chromatography of their methyl esters after isolation by column chromatography on silica gel. J Chromatogr B Biomed Appl 666:1-12, 1995
28. 28. WU Y, MONNIER V, FRIEDLANDER M: Reliable determination of furosine in human serum and dialysate proteins by high-performance liquid chromatography. J Chromatogr B 667:328-3.12, 1995
29. 29. ODEIITI P, FOGARTY J, SELL DR, MONNIER VM: Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes 41:153-159, 1992
30. 30. EL GAWISH AH, GLOMB M, FRIEDLANDER M, MONNIER VM: Involvement of hydrogen peroxide in collagen crosslinking by high glucose in vitro and in vivo. J Biol Chem 271:1296-4-12971, 1996
31. 31. TAKAHASHI M, OHISHI T, AOSHIMA H, KAWANA K, KUSHIDA K, INOUE T, HORIUCHI K: The Maillard protein cross-link pentosidine in urine from diabetic patients. Diabetologia 36:664-667, 1993
32. 32. TAKAHASHI M, KUSHIDA K, KAWANA K, ISHIHARA C, DENDA M, INOUE T, HORIUCHI K: Quantification of the cross-link pentosidine in serum from normal and uremic subjects. Clin Chem 39:2162-2165, 1993
33. ε (Carboxymethyl) Lysine in End Stage Renal Disease: Role of Dialysis Clearance. London, Royal Society of Chemistry, 1998
34. 34. ARAKI A, GLOMB M, MONNIER V, editors: Formation of Aminoguanidine-Triazine Compounds During Sugar Antoxidation and Glycoxidation in Vitro and in Vivo. London, Royal Society of Chemistry, 1997
35. 35. NIWA T, TAKEDA N, MIYAZAKI T, YOSHIZUMI H, TATEMATSU A, MAEDA K, OHARA M, TOMIYAMA S, NIIMURA K: Elevated serum levels of 3-deoxyglucosone, a potent protein-cross-linking intermediate of the Maillard reaction, in uremic patients. Nephron 69:438-443, 1995
36. 36. WEISLANDF.R A, FORSBACK G, SVENSSON E, LINDEN T: Cytotoxicity, pH and glucose degradation products in four different brands of PD fluid. Adv Perit Dial 12:57-60, 1996
37. 37. MIYATA T, WADA Y, CAL Z, IIDA Y, HORIL K, YASUDA Y, MAEDA K, KURAKOWA K, VAN YPERSELE DE SIRIHOU C: Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end stage renal failure. Kidney Int 51:1170-1181, 1997
38. 38. DEGENHARDT T, GRASS L, REDDY S, THORPE: S, DIAMANDIS E, BAYNES J: The serum concentration of the advanced glycation end-product N epsilon-(carboxymethyl) lysine is increased in uremia. Kidney Int 52:1064-1067, 1997
39. 39. BROWNELLE M, CERAMI A, VLASSARA H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318:1315-1321, 1988
40. 40. BUCALA R, VLASSARA H: Advanced glycosylation end products in diabetic renal and vascular disease. Am J Kidney Dis 26:875-888. 1995
41. 41. DYER D, DUNN J, THORPE S, BAILLE K, LYONS T, MCCANCE D, BAYNES J: Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 91:2463-2469, 1993
42. 42. REQUENA J, AHMED M, FOUNTAIN C, DEGENHARDT T, REDDY S, PIREZ C, LYONS T, JENKINS A, BAYNES J, THORPE S: Carboxymethylethanolamine, a biomarker of phospholipid modification during the Maillard reaction in vivo. J Biol Chem 272:17473-17479, 1997
43. 43. JADOUL M, UEDA Y, YASUDA Y, SAITO A, ROBERT A, ISHIDA N, KUROKAWA K, VAN YPERSELE DE STRIHOU C, MIYATA T: Influence of hemodialysis membrane type on pentosidine plasma level, a marker of "carbonyl stress." Kidney Int 55:2487-2492, 1999
44. 44. MIYATA T, UEDA Y, YAMADA Y, IZUHARA Y, WADA T, JADOUL M, SAITO A, KUROKAWA K, VAN YPERSELE DE SIRIHOU C: Accumulation of carbonyls accelerates the formation of pentosidine, and advanced glycation end product: carbonyl stress in uremia. J Am Soc Nephrol 9:2349-2356, 1998
45. 45. BULIITUDE F, NEWHAM S: Identification of some abnormal metabolites in plasma from uremic subjects. Clin Chem 21:1329-1334, 1975
46. 46. ROBOZ J, KAPPAIOS D, HOLLAND J: Polyol concentrations in serum during hemodialysis. Clin Chem 36:2082-2086, 1990
47. 47. LINDEN T, FORSBACK G, DEPPICH R, HENLE T, WIESLANDFR A: 3-Deoxyglucosone, a promoter of advanced glycation end products in fluids for peritoneal dialysis. Perit Dial Int 18:290-293, 1998
48. 48. WIIKO-SAKSAT V, FRIEDI ANDER M. KHOA T, CAPEILLERE-BLANDIN C, NGUYEN A, CANTELOUP S, DAYER J-M, JUNGERS P, DRUEKE T, DESCAMPS-LATSCHA B: Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immnnol 161:2524-2532, 1998
49. 49. HALLIWELL B, GUTTERIDGE J: Free Radicals in Biology and Medicine. Oxford, Clarendon Press, 1989
50. 50. WEISS M, SAXENA A, MONNIER V: Pharmacological modulation of AGEs: A unique role for redox-active metal ions. Perit Dial Int 19:S63-S68, 1999
51. 51. SAXENA A, SAXENA P, WU X, OBRENOVICH M, WEISS M, MONNIER V: Protein aging by carboxymethylation of lysines generates sites for divalent metal and redox active copper binding: Relevance to diseases of glycoxidative stress. Biochem Biophys Res Commun 260:332-339, 1999